戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1           The all-cause mortality risk score was calculated using 0.0398 x (age) + 0.516 x (renal ins
2                          The pregnancy start was calculated using 1) a validated algorithm to estimat
3                                         NSES was calculated using 1990 US Census data (block groups;
4 ht ventricular free wall longitudinal strain were calculated using 2-dimensional speckle-tracking ech
5             A visual distortions index (%DI) was calculated using 3-dimensional threshold Amsler grid
6  (in 2D axis), height and size of scatterers are calculated using a feedforward deep neural network (
7                    The posterior probability is calculated using a Bayesian model that integrates pri
8                                        Power is calculated using a semi-parametric simulation-based a
9              The CMRglc of each brain region was calculated using a 3-compartment model and an operat
10              The CMRglc of each brain region was calculated using a 3-compartment model and an operat
11            The surface area that was sprayed was calculated using a commercially available software w
12                            Relative survival was calculated using a conditional approach and expresse
13 ificity of the ROP diagnosis by experts that was calculated using a consensus reference standard diag
14               The effect of vWF on prognosis was calculated using a Cox regression model.
15                                           FI was calculated using a defined approach.
16                       Pooled odds ratio (OR) was calculated using a fixed- or random-effect model.
17                                A third MR-AC was calculated using a model-based, postprocessing appro
18                           The ctDNA fraction was calculated using a novel algorithm designed for the
19 of the binding between vancomycin and Zn(II) was calculated using a novel fluorometric assay, and NMR
20 ions, and K(i) in individual bone metastases was calculated using a previously validated method.
21  a patient level, the diagnostic performance was calculated using a sensitivity analysis, in which eq
22                           Kinetic parameters were calculated using a 1-tissue-compartment model and c
23  and mesio-lingual [ML]) and different PMPEs were calculated using a 15% cut-off point: 1) full-mouth
24     Odds ratios and 95% confidence intervals were calculated using a conditional logistic regression
25                                    T1 values were calculated using a curve-fitting algorithm on avera
26      Monthly age- and sex-standardized rates were calculated using a direct method of standardization
27 zing the fMRI data, for AEA and 2-AG ANCOVAs were calculated using a full factorial model, with condi
28                  Individual estimates of REi were calculated using a maximum likelihood procedure to
29                      Misclassification rates were calculated using a Monte-Carlo 5-fold cross-validat
30 idated method and pharmacokinetic parameters were calculated using a non-compartmental model.
31 d ID(90)) of target-mediated antibody uptake were calculated using a Patlak transformation.
32                         Daptomycin exposures were calculated using a published population pharmacokin
33               Risk ratios (RRs) with 95% CIs were calculated using a random effects model, and Mantel
34                            Summary estimates were calculated using a random effects model.
35 ios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall an
36                            Summary estimates were calculated using a random-effects model.
37 os (RRs), and 95% confidence intervals (CIs) were calculated using a random-effects model.
38 pillary density (CD) and vessel density (VD) were calculated using a reflectance-compensated algorith
39                   The life-cycle inventories were calculated using a stoichiometric life-cycle invent
40  size estimates for disease-modifying trials were calculated using a time-to-event analysis.
41         Driving times for 3.79x10(7) persons were calculated using a total of 3.88x10(7) available ro
42                           The NEI-VFQ scores were calculated using a traditional subscale scoring alg
43                                        SUVRs were calculated using AAL (Automated Anatomical Labeling
44                      DNA methylation age can be calculated using age-related CpGs and might reflect b
45 ed using the fibrosis 4 index (FIB-4), which is calculated using age, aminotransferases, and platelet
46                                PSI-90 scores were calculated using Agency for Healthcare Research and
47 The proportion of attestations by EHR vendor was calculated using all attestations for each vendor.
48                       The years of life lost were calculated using all adult nontraumatic emergency m
49     Standardized mean differences (Hedges g) were calculated using all outcomes reported in the trial
50 ed enamel and dentin interface area (E%, D%) were calculated using Amira software.
51 ry steps in the various competing mechanisms are calculated using an ONIOM-based approach in which th
52           An effective mobility value, zeta, is calculated using an assigned atomic mobility value wi
53                       A time trend of CPPopt was calculated using an automated curve-fitting method t
54                             Vascular density was calculated using an automated image thresholding met
55                The stop-signal reaction time was calculated using an ex-Gaussian Bayesian model.
56 er operating curves (AUCs) of the two models were calculated using an independent test set.
57    Factor scores of clinical psychopathology were calculated using an item-wise confirmatory bifactor
58 res of the most important words of interest, were calculated using Anthropac by domain and group.
59       Diagnostic accuracy versus FFR </=0.80 was calculated using binary cutoff values of </=0.90 for
60       End-systolic and end-diastolic volumes were calculated using blood pool images and applied to o
61                    Patient complication risk was calculated using both the universal calculator and a
62                               Rate constants were calculated using canonical variational transition s
63                              DLW expenditure was calculated using chamber-determined RQ either unadju
64                                    The QALYs were calculated using Child Depression Rating Scale-Revi
65                                   Recoveries were calculated using clean soils spiked with 100, 500,
66  tumors of the conjunctiva and eyelid margin were calculated using clinical examination with slitlamp
67 cific rates of adverse event free admissions were calculated using colorectal procedures as an exampl
68                  Volume of the Schlemm canal was calculated using commercially available 3-dimensiona
69                    Subhazard ratios (sub-HR) were calculated using competing risk regression analysis
70                   Cumulative incidence rates were calculated using competing risk survival statistics
71 ith caution due to high heterogeneity, which was calculated using comprehensive meta-analysis statist
72 -HOMO-LUMO energy gap, hardness and softness were calculated using computational chemistry tools.
73 atios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic regression mo
74                             Odds ratios (OR) were calculated using conditional logistic regression.
75 risks (RR) and 95% confidence intervals (CI) were calculated using conditional logistic regression.
76 the curve (AUC), while predictive parameters were calculated using contingency tables.
77               Several autoregulation indices were calculated using correlation and wavelet methods, i
78 ios (HRs) and 95% confidence intervals (CIs) were calculated using Cox modeling, adjusting for risk f
79 -transformed IL-6, hsCRP, and D-dimer levels were calculated using Cox models.
80                                Hazard ratios were calculated using Cox proportional hazard models in
81             Hazard ratios (HR) for mortality were calculated using Cox proportional hazards regressio
82              Hazard ratios (HRs) and 95% CIs were calculated using Cox proportional hazards regressio
83 expectancy and years of life saved after AMI were calculated using Cox proportional hazards regressio
84 d ratios (HRs) and 95% CIs for breast cancer were calculated using Cox proportional hazards regressio
85                          Hazard ratios (HRs) were calculated using Cox regression analysis.
86 otential treatment bias, hazard ratios (HRs) were calculated using Cox regression and were tested aga
87 s (HRs) of 42-day and one-year EVB mortality were calculated using Cox regression model.
88 D increment of log-transformed cystathionine were calculated using Cox regression modeling.
89  [hazard ratio]) and 95% CIs for incident AF were calculated using Cox regression models adjusted for
90 nd the reliability of the pass/fail decision were calculated using Cronbach alpha and Subkoviak metho
91                      Automated PPCMv density was calculated using custom Matlab software in inner and
92            alpha- and beta-diversity metrics were calculated using DADA2-based clustering.
93     Adherence (< 4.5 years or >/= 4.5 years) was calculated using data from six monthly clinical visi
94                          Risk of death score was calculated using data submitted to the Australia and
95  cortisol, major depression, and neuroticism were calculated using data from large genome wide associ
96                     Voxelwise volume changes were calculated using deformation-based morphometry, and
97 , activation free energies of chemical steps were calculated using density functional theory (DFT).
98 nism, and the activation barriers to gearing were calculated using density functional theory.
99 m(2)h) and casting CS (0.7 +/- 0.01 L/m(2)h) were calculated using device.
100                                         PRSs were calculated using discovery effect size estimates we
101 ociated with protocolized laboratory testing were calculated using dollar amounts representing 2017 o
102                            Displacement in z was calculated using dye-filled blood vessels as an anat
103 nd the left ventricular ROI, and mean counts were calculated using Elip-ROI and RG-ROI techniques.
104           The recurrence rate for each study was calculated using events/person years of follow-up (P
105 % CIs for the incidence rate of transmission were calculated using exact Poisson methods.
106 owever successful fragile site repair cannot be calculated using existing techniques.
107                      Absolute concentrations were calculated using extinction coefficients of each of
108                           HOMA-B and HOMA-IR were calculated using FG and FI data.
109        The identity by descent probabilities were calculated using FlexQTL software and included in t
110 ht pools of patient samples, and specificity was calculated using four clades of C. auris and closely
111            Adjusted prevalence ratios (aPRs) were calculated using generalized estimating equations.
112 imorbidity in relation to sensitization ever were calculated using generalized estimating equations.
113 reast cancer incidence and mortality in 2018 were calculated using GLOBOCAN data.
114 within 7 days of hospital outpatient surgery were calculated using hierarchical logistic regression m
115                           IR and sensitivity were calculated using HOMA-IR and Matsuda indices.
116 -lamina cribrosa pressure difference (TLCPD) was calculated using ICP and IOP together with geometric
117  Case fatality rates (CFRs) during 2010-2017 were calculated using incidence data from the Sabah Depa
118 an differences, and 95% confidence intervals were calculated using independent sample t-tests.
119     Study-specific adjusted effect estimates were calculated using inverse probability of treatment-w
120                           Time to recurrence was calculated using Kaplan Meier estimates.
121 Cumulative survival free from adverse events was calculated using Kaplan-Meier curves and Cox proport
122                                  Net failure was calculated using Kaplan-Meier estimates, and adjuste
123                          The risk of relapse was calculated using Kaplan-Meier methods, and predictor
124 r recurrence, and melanoma-related mortality were calculated using Kaplan-Meier estimates, and Cox pr
125                              Assay agreement was calculated using kappa statistics.
126                        Interreader agreement was calculated using kappa-statistics, and semiquantitat
127 epression Scale Short Form, and trajectories were calculated using latent class growth curve analysis
128   Complexity of the resulting binary strings was calculated using Lempel-Ziv ('76 & '78) and Titchene
129      Lung cancer excess lifetime risks (ELR) were calculated using life tables accounting for all-cau
130                  The rate of change of ALCSD was calculated using linear mixed effects models.
131 rogression rate globally and within a sector was calculated using linear mixed modeling.
132                   Global VF progression rate was calculated using linear regression on mean deviation
133                    Sectoral progression rate was calculated using linear regression on the sensitivit
134                         Population estimates were calculated using linear interpolation from the 2000
135 sociations of LTL with each adiposity marker were calculated using linear mixed models with a random
136 -based heritability and genetic correlations were calculated using linkage disequilibrium score regre
137                                    Incidence was calculated using livebirths in 2014 (after adjustmen
138  program, and annual percent change in rates was calculated using log-linear regression.
139 amycin-resistant beta-hemolytic streptococci were calculated using log-binomial regression, controlli
140                Volume-of-distribution images were calculated using Logan plots and analyzed on a volu
141        Propensity score (PS) for insulin use was calculated using logistic regression including prede
142                                  Odds ratios were calculated using logistic regression to account for
143 , and 45, other high-risk types, and any HPV were calculated using logistic regression.
144                          Brain-predicted age was calculated using machine-learning analysis, trained
145  medians for estimated episode of care costs were calculated using marginal longitudinal two-part reg
146 5-2018 youth and adult MBS utilization rates were calculated using MBSAQIP data (numerator) and NHANE
147                             Procedural costs were calculated using Medicare reimbursement rates.
148                     The rate of PCT thinning was calculated using mixed effects models.
149  tuberculin skin testing, and relative risks were calculated using modified Poisson regression models
150 odeficiency virus (HIV) status (adults only) were calculated using modified Poisson regression, with
151                          Radiation dosimetry was calculated using mouse biodistribution data and bloo
152 ere reported at each visit, and trajectories were calculated using MPlus.
153  air pollution, and proximity to major roads were calculated using multiple linear mixed models with
154                                  Odds ratios were calculated using multivariable conditional logistic
155                                   OS and PFS were calculated using multivariable Cox proportional haz
156                         Adjusted odds ratios were calculated using multivariable logistic regression.
157 ing antibiotic use in BLA and non-BLA groups were calculated using multivariable negative binomial mo
158 ing antibiotic use in BLA and non-BLA groups were calculated using multivariable negative binomial mo
159  circulating concentration) and liver cancer were calculated using multivariable-adjusted conditional
160 oubling of circulating concentration) and LC were calculated using multivariable-adjusted conditional
161 Adjusted odds ratios (OR) for each diagnosis were calculated using multivariate logistic regression m
162                   Fiber lenght density (FLD) was calculated using NeuronJ and expressed in mm/mm2.
163 d and the diffusion coefficients at 298.15 K were calculated using NMR spectroscopy.
164                            MPA PK parameters were calculated using non-compartmental analysis.
165                            MPA PK parameters were calculated using noncompartmental analysis.
166 h mass-spectroscopy (UPLC) and PK parameters were calculated using noncompartmental methods.
167 r gram (%ID/g) was determined, and dosimetry was calculated using OLINDA/EXM, version 1.0.
168 rgan doses and the whole-body effective dose were calculated using OLINDA 2.0.
169 nd radiation-absorbed doses to normal organs were calculated using OLINDA.
170                               Absorbed doses were calculated using OLINDA/EXM 1.0.
171 oses to individual organs and the whole body were calculated using OLINDA/EXM 1.2 for the standard ma
172                               Absorbed doses were calculated using OLINDA/EXM, version 1.1.
173            Rates of visual field progression were calculated using ordinary least-squares linear regr
174 ity of TFS at 3 years given survival to S2P) was calculated using parametric conditional survival ana
175             Glucose metabolic rate (MR(glc)) was calculated using Patlak linear regression analysis.
176                                 K(i) and CBV were calculated using Patlak modelling for manual region
177 ize-exclusion chromatography, and PTM levels were calculated using peptide mapping.
178 , interobserver, and scan-rescan variability was calculated using percentage coefficient of variation
179 predictive power of the different parameters was calculated using permutation.
180         The probability of target attainment was calculated using pharmacodynamic targets of percenta
181                     Cerebral oxygen delivery was calculated using phase contrast angiography and pre-
182 red LED materials with different wavelengths was calculated using photoluminescence (PL) spectroscopy
183                 Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk
184 ted risk ratios for asthma at ages 5-9 years were calculated using Poisson regression models and pool
185 alizations and 30-day HF re-hospitalizations were calculated using Poisson regression models.
186       Adjusted incidence rate ratios (aIRRs) were calculated using Poisson regression, adjusting for
187 ates (illnesses per sample) by treatment arm were calculated using Poisson regression.
188                        Incidence rate ratios were calculated using Poisson regressions while adjustin
189 ), and the degree of polarization uniformity was calculated using polarization-sensitive optical cohe
190  events in blacks and 1660 events in whites) were calculated using pooled Mantel-Haenszel estimates w
191 similar to pack-years of cigarette smoking), were calculated using predicted BMIs.
192  The local conduction velocity at each point was calculated using previously established methods.
193 tion between markers and HBeAg seroclearance were calculated using proportional hazards regression, a
194 ible indispensable amino acid scores (DIAAS) was calculated using published data on amino acids' dige
195             Prevalence of early and late AMD was calculated using random-effects meta-analysis strati
196 orrelations between cortisol levels and HCVs were calculated using random effects.
197 ifferences and standardized mean differences were calculated using random-effect meta-analyses.
198       Pooled sensitivities and specificities were calculated using random-effect meta-analyses.
199  Pooled standardized mean differences (SMDs) were calculated using random-effect models.
200  and during and after the first year of ART, were calculated using random-effects meta-analyses.
201                          Pooled effect sizes were calculated using random-effects meta-analysis.
202 ifference for continuous outcome with 95% CI were calculated using random-effects model meta-analysis
203                                 Effect sizes were calculated using random-effects models for cognitiv
204  Pooled estimates of incidence and mortality were calculated using random-effects models.
205                       Summary relative risks were calculated using random-effects models.
206         Pooled odds ratios (ORs) with 95% CI were calculated using random-effects models.
207                            Summary estimates were calculated using random-effects models.
208            Thresholds for outcome prediction were calculated using receiver operating curves.
209 m homes with cats or dogs from those without were calculated using receiver-operating characteristics
210                       Height SD scores (SDS) were calculated using recent national or European growth
211 c Retinopathy Study (appETDRS) letter score, was calculated using recorded Snellen visual acuities.
212 cidence, outcomes, and trends from 2009-2014 were calculated using regression models and compared wit
213                       Changes in KCCQ scores were calculated using repeated measures analysis of cova
214 fferences (MD), and 95% confidence intervals were calculated using RevMan 5.3.
215 ory ratio is a simple bedside index that can be calculated using routinely measured respiratory varia
216                 Diagnostic performance of CT was calculated using RT-PCR as the reference standard.
217 m 440,526 participants from UK Biobank, eGFR was calculated using serum creatinine, cystatin C (eGFRc
218 al rate of change in these neural phenotypes was calculated using SOLAR (Sequential Oligogenic Linkag
219     Phylogenetic community structure metrics were calculated using species pools that differed in spa
220                               All shieldings are calculated using state-optimized pi-space complete-a
221 disease prevalence and treatment eligibility were calculated using stochastic simulation and populati
222 s for the development of Alzheimer's disease were calculated using summary statistics from the larges
223  peak systolic circumferential strain (PSCS) was calculated using tagging and feature-tracking softwa
224 ceived >/=14 days before delivery; trimester was calculated using Tdap date, infant's date of birth,
225 ier relaxation times for electrons and holes are calculated using the Bardeen and Shockley's deformat
226                       Expansive growth rates are calculated using the calculated Pi values and are co
227  constant and the respective half-life could be calculated using the radioactive decay equations base
228 TER are computed based on the SE of MER that is calculated using the bootstrap method.
229                            % neurite density is calculated using the normalize local contrast algorit
230 ge-standardized prevalence of retinal emboli was calculated using the 2010 Singapore adult population
231                       Relative survival also was calculated using the actuarial method.
232                  Compound annual growth rate was calculated using the adjusted data.
233                          Predicted morbidity was calculated using the American College of Surgeons Na
234                             Ideal toric axis was calculated using the back-calculator astigmatismfix.
235                     A wearable BCG-based PTT was calculated using the BCG and photoplethysmogram (PPG
236                       Dead space ventilation was calculated using the Bohr equation.
237 y determining the confidence interval, which was calculated using the bootstrap re-sampling technique
238 reviously validated Healthy Purchasing Score was calculated using the cafeteria traffic-light labelin
239                   Medical comorbidity burden was calculated using the Charlson Comorbidity Index-pati
240  CRS/HIPEC caseload affecting the 90-day POM was calculated using the Chi-squared Automatic Interacti
241                  Distribution of RPE melanin was calculated using the dataset from multi-contrast OCT
242 thermal challenge response (DeltaSBF/DeltaT) was calculated using the following formula: (SBF37-SBFBT
243  the diaphragm during inspiration (TFdi,max) was calculated using the following formula: TFdi,max = (
244                                          SNR was calculated using the formula: SNR=signal intensity (
245                             Overall survival was calculated using the Kaplan-Meier method with the lo
246                             Overall survival was calculated using the Kaplan-Meier method.
247  years of follow-up; postrecurrence survival was calculated using the Kaplan-Meier method.
248                         The primary endpoint was calculated using the least squares mean at each time
249                        The magnitude of RAPD was calculated using the log of the ratio of the constri
250                              Odds ratio (OR) was calculated using the Mantel-Haenszel method.
251 ion and estimated glomerular filtration rate was calculated using the Modification of Diet in Renal D
252         Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal D
253                                          PHA was calculated using the non-laboratory Framingham CVD r
254                                    Inference was calculated using the non-parametric bootstrap.
255                                    Inference was calculated using the nonparametric bootstrap.
256                          Radiation dosimetry was calculated using the OLINDA/EXM software.
257                Ten-year predicted ASCVD risk was calculated using the pooled cohort risk equations.
258                   Preoperative frailty score was calculated using the progressive Clinical Frailty Sc
259  abundance across the periodontal phenotypes was calculated using the R package DESeq2.
260           The risk of lymph node involvement was calculated using the Roach formula and compared with
261                                         BPND was calculated using the simplified reference tissue mod
262         Mean change in DA function over time was calculated using the slope of linear regression fits
263 d the exchange of water between these layers was calculated using the van Genuchten equation.
264        For each protocol, a complexity score was calculated using the variables predicting warfarin d
265                 Lung Injury Prediction Score was calculated using the worst values within the 12 hour
266 s determined and then TVC values (CFU/cm(2)) were calculated using the calibration equation.
267                                BPND and SUVR were calculated using the cerebellar cortex as a referen
268     Nondisplaceable binding potential values were calculated using the cerebellum as a reference regi
269 lectronic medical records, and complications were calculated using the Clavien-Dindo classification.
270 pecificity of image grading for plus disease were calculated using the clinical examination finding a
271                          Hazard ratios (HRs) were calculated using the Cox proportional hazard model
272 vitreal injections relative to those without were calculated using the Cox proportional hazard model.
273                                   ULN values were calculated using the cutoff levels suggested by the
274                                Comorbidities were calculated using the Elixhauser Comorbidity Index.
275 ine) and genome-wide average DNA methylation were calculated using the HumanMethylation 450 K BeadChi
276  probabilities with 95% confidence intervals were calculated using the Kaplan-Meier estimator stratif
277                           Survival estimates were calculated using the Kaplan-Meier method, and multi
278                       Survival probabilities were calculated using the Kaplan-Meier method, and the a
279                               Survival rates were calculated using the Kaplan-Meier method.
280              Recurrence-free survivals (RFS) were calculated using the Kaplan-Meier method.
281                         Time-to-event curves were calculated using the Kaplan-Meier method.
282 fety analyses, odds ratios (ORs) and 95% CIs were calculated using the Mantel-Haenszel method.
283                            GrimAge estimates were calculated using the methylation age calculator.
284                              Radiation doses were calculated using the OLINDA/EXM software, version 2
285 th respect to the foveal center in both eyes were calculated using the polar transformation method in
286                        HIV genetic distances were calculated using the polymerase region.
287         Generated weighted means and 99% CIs were calculated using the reported means (SDs or SEs).
288   Nondisplaceable binding potentials (BPNDs) were calculated using the simplified reference tissue mo
289                                 VE estimates were calculated using the test-negative design.
290                                 Flow volumes were calculated using the Water Supply Sustainability In
291 er-arm circumference, and head circumference were calculated using the WHO 2006 growth standards.
292 d prostate segments, and optimal SUV cutoffs were calculated using the Youden index for each radiotra
293 tandardized morbidity ratios (SMRs) for 2013 were calculated, using the nondiabetic population as a r
294 substance classes, the relative mass defects were calculated using theoretical molecular masses.
295  entropy and melting temperature of aluminum were calculated using this machine learning potential.
296 ignal of global and contralateral hemisphere was calculated using TSA.
297  In vitro radiopharmaceutical concentrations were calculated using urine sampling obtained immediatel
298                Transplant wait-listing rates were calculated using US Renal Data System data.
299 ernate Healthy Eating Index 2010 (AHEI-2010) were calculated using validated food-frequency questionn
300  body fat (BF) and skeletal muscle mass (SM) were calculated using validated formulas (including wais

 
Page Top